December 20, 2022

VIA EDGAR SUBMISSION

Securities and Exchange Commission

Division of Corporation Finance

100 F Street, NE

Washington, DC 20549

 

Attention:

Lauren Hamill

Tim Buchmiller

 

Re:

Syros Pharmaceuticals, Inc.

Registration Statement on Form S-3

File No. 333-267888

Request for Acceleration

Ladies and Gentlemen:

Pursuant to Rule 461 under the Securities Act of 1933, as amended, Syros Pharmaceuticals, Inc. hereby requests acceleration of the effective date of its Registration Statement on Form S-3 (File No. 333-267888), so that it may become effective at 4:00 p.m., Eastern Time, on December 22, 2022, or as soon as practicable thereafter.

 

Very truly yours,
SYROS PHARMACEUTICALS, INC.
By:  

/s/ Gerald E. Quirk

Name:   Gerald E. Quirk
Title:   Chief Legal Officer